Our Story
Redefining BPH Care for Today’s Urology Practice.
Led and co-founded by practicing urologist Adam Kadlec, Rivermark Medical creates solutions grounded in real-world clinical needs.
Restore Flow, Preserve Options.
FloStent is a first-line device treatment for BPH, delivered in the outpatient setting during a routine cystoscopy using a standard flexible cystoscope. The FloStent is designed to immediately restore normal urinary flow, minimize patient recovery time, and preserve future treatment options—enabling a continuum of care for both patients and providers.
Led and co-founded by practicing urologist Adam Kadlec, Rivermark Medical creates solutions grounded in real-world clinical needs.
The FloStent System is currently available at select sites across North America and Australia as part of the RAPID-3 Clinical Study. If you qualify and choose to participate, you will receive comprehensive, study-related care at no cost. In addition, you will be compensated for your time and travel associated with scheduled visits to your study doctor’s office. These visits provide an opportunity to share your experiences, monitor your progress, and contribute to advancing care for men with BPH.
See if You Qualify
